The American College of Cardiology has released a sweeping 2026 scientific statement consolidating evidence-based recommendations for antiplatelet therapy across the full spectrum of atherosclerotic cardiovascular disease (ASCVD). The statement covers everything from aspirin use in primary prevention to dual antiplatelet therapy (DAPT) de-escalation after acute coronary syndrome — and flags bleeding risk as the biggest ongoing challenge. Think of it as a one-stop-shop for clinicians navigating a crowded field of guidelines.
The American College of Cardiology (ACC) has published a 2026 scientific statement in the Journal of the American College of Cardiology that consolidates antiplatelet therapy recommendations across the entire ASCVD spectrum — from primary prevention to post-revascularization management. Unlike condition-specific guidelines, this statement brings together guidance for acute coronary syndrome (ACS), chronic coronary disease, peripheral artery disease (PAD), and cerebrovascular disease in one place.
Key highlights include a preference for prasugrel or ticagrelor over clopidogrel in ACS patients undergoing PCI, with growing evidence supporting early de-escalation to clopidogrel monotherapy within weeks to months rather than years. Low-dose aspirin remains an option for primary prevention in adults aged 40–70 with elevated cardiovascular risk, but should be avoided in those over 70. Rivaroxaban 2.5 mg twice daily plus aspirin 81 mg may benefit select high-risk patients with stable CAD or PAD.
Key Takeaways:
Why it matters: With multiple overlapping guidelines and complex patient profiles, clinicians have long needed a unified reference. This ACC statement fills that gap — and signals a broader shift toward shorter, more tailored antiplatelet regimens that balance ischemic protection with bleeding safety.
